"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 4910-4918

  Perreira, Melissa ^a   Jiang, Jian Kang ^a   Klutz, Athena M ^a   Gao, Zhan Guo ^a   Shainberg, Asher ^a,b   Lu, Changrui ^a   Thomas, Craig J ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 MORPHOLINOANILINO) N6 CYCLOHEXYLADENINE; 2 (PHENYLAMINO) N6 CYCLOHEPTYLADENINE; 2 (PHENYLAMINO) N6 CYCLOHEXYLADENINE; 2 (PHENYLOXY) N6 CYCLOHEXYLADENINE; 2 BENZYLAMINE; 2 PHENYLAMINE; 2 PHENYLAMINO N6 NORBORNYLADENINE; 6 CHLORO 2 FLUOROPURINE; ADENINE; ADENINE DERIVATIVE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; CYCLIC AMP; CYCLOALKANE; FORSKOLIN; FUNCTIONAL GROUP; PURINE DERIVATIVE; REVERSINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL; COMPETITIVE INHIBITION; DEDIFFERENTIATION; DIFFERENTIATION; DRUG EFFECT; DRUG SELECTIVITY; DRUG SYNTHESIS; INHIBITION KINETICS; METHYLATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR BLOCKING; SCHILD ANALYSIS; STRUCTURE ACTIVITY RELATION;

ADENINE; ANIMALS; BINDING, COMPETITIVE; CELL DIFFERENTIATION; CELL LINE; CRICETINAE; CRICETULUS; CYCLIC AMP; HUMANS; MICE; MORPHOLINES; MUSCLE CELLS; PURINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 22744459205     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050221l     Document Type: Article

References (34)

1. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. M. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol. Rev. 2001, 53, 527-552.
2. Yao, L.; Burbiel, J. C.; Maass, A.; Müller, C. E. Adenosine receptor agonists: From basic medicinal chemistry to clinical development. Expert Opin. Emerging Drugs 2003, 8, 537-576.
3. 3 adenosine receptor agonists. J. Med. Chem. 2005, 48, 1745-1758, and references therein.
4. 3 selective ligands containing bioisosteric isoxazoles. Bioorg. Med. Chem. Lett. 1998, 8, 1767-1770.
5. Lee, K.; Ravi, R. G.; Ji, X.-d.; Marquez, V. E.; Jacobson, K. A. Ring-constrained (N) methanocarba-nucleosides as adenosine receptor agonists: Independent 5′-uronamide and 2′-deoxy modifications. Bioorg. Med. Chem. Lett. 2001, 11, 1333-1337.
6. Ohno, M.; Gao, Z. G.; Van Rompaey, P.; Tchilibon, S.; Kim, S. K.; Harris, B. A.; Blaustein, J.; Gross, A. S.; Duong, H. T.; Van Calenbergh, S.; Jacoboson, K. A. Modulation of adenosine receptor affinity and intrinsic efficacy in nucleosides substituted at the 2-position. Bioorg. Med. Chem. 2004, 12, 2995-3007.
7. 6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg. Med. Chem. Lett. 2004, 12, 2021-2034.
8. 3 adenosine receptors. Biochem. Pharm. 2003, 65, 1675-1684.
9. 1 adenosine receptor ligands. A comparison with the corresponding adenines and 8-azaadenines. Eur. J. Med. Chem. 2003, 38, 983-990.
10. 2b ligands. J. Med. Chem. 2002, 45, 3271.
11. Klotz, K.-N.; Kachler, S.; Lambertucci, C.; Vittori, S.; Volpini, R.; Cristalli, G. 9-Ethyladenine derivatives as adenosine receptor antagonist: 2- And 8-substitution results in distinct selectivities. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 629-634.
12. 1 adenosine receptor. J. Med. Chem. 1991, 34, 2877-82.
13. 3 adenosine receptors. J. Med. Chem. 1995, 38, 1720-35.
14. 1 adenosine receptors. J. Pharmacol. Exp. Ther. 1996, 276, 490-9.
15. Martin, P. L.; Ueeda, M.; Olsson, R. A. 2-Phenylethoxy-9-methyladenine: An adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and the coronary vessels from the guinea pig. J. Pharmacol. Exp. Ther. 1993, 265, 248-53.
16. Laufer, S. A.; Domeyer, D. M.; Scior, T. R.; Albrecht, W.; Hauser, D. R. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J. Med. Chem. 2005, 48, 710-22.
17. Schulte, G.; Fredholm, B. B. Signaling from adenosine receptors to mitogen-activated protein kinases. Cell. Signal. 2003, 15, 813-827.
18. Chen, S.; Zhang, Q.; Wu, X.; Schultz, P. G.; Ding, S. Dedifferentiation of lineage-committed cells by a small molecule. J. Am. Chem. Soc. 2004, 126, 410-411.
19. Ding, S.; Gray, N. S.; Wu, X.; Ding, Q.; Schultz, P. G. A combinatorial scaffold approach toward kinase-directed heterocycle libraries. J. Am. Chem. Soc. 2002, 124, 1594-1596.
20. 3 adenosine receptor. Mol. Pharmacol. 1994, 45, 978-982.
21. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes-Characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 357, 1-9.
22. Gao, Z. G., Mamedova, L., Chen, P., Jacobson, K. A. 2-Substituted adenosine derivatives: Affinity and efficacy at four subtypes of human adenosine receptors. Biochem. Pharmacol. 2004, 68, 1985-1993.
23. 1-receptor antagonist effects of N-0861. Clin Pharmacol Ther. 1998, 64, 536-541.
24. 1 adenosine receptor. Biochem. Pharm. 1999, 58, 167-170.
25. 2b Receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension 2000, 35, 267-272.
26. 3 adenosine receptor. Eur. J. Cancer 2000, 36, 1452-1458.
27. Bradford, M. M. A rapid and sensitive method for the quatitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1990, 189, 231-234.
28. Nordstedt, C.; Fredholm, B. B. A modification of a protein-binding method for the rapid qualification of cAMP in cell-culture supernatants and body fluid. Anal. Biochem. 1990, 189, 231-234.
29. Post, S. R.; Ostrom, R. S.; Insel, P. A. Biochemical methods for detection and measurement of cyclic AMP and adenylyl cyclase activity. Methods Mol. Biol. 2000, 126, 363-374.
30. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 1959, 14, 48-58.
31. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
32. 3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr. Eye Res. 2005, 30, in press.
33. 3 receptor ligands: New potential therapy for the treatment of glaucoma. Bioorg. Med. Chem. Lett. 2004, 14, 3775-3779.
34. 3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J. Immunol. 2004, 173, 1380-9.